Xilio Therapeutics (XLO) Return on Sales (2024 - 2026)

Xilio Therapeutics (XLO) has 3 years of Return on Sales data on file, last reported at 0.01% in Q1 2026.

• For the quarter ending Q1 2026, Return on Sales rose 4.0% year-over-year to 0.01%; the trailing twelve-month figure through Mar 2026 stood at 0.01% (up 5.0% YoY), and the FY2025 full-year result was 0.04%, up 23.0% from the prior year.
• Return on Sales fell to 0.01% in Q1 2026, from 0.01% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 0.0% in Q3 2025 to a low of 0.08% in Q4 2024.
• A 3-year average of 0.04% and a median of 0.03% in 2025 frame the typical range for Return on Sales.
• Across the five-year window, Return on Sales advanced 7 bps in 2025 and advanced 4 bps in 2026, its largest moves.
• Tracing XLO's Return on Sales over 3 years: stood at 0.08% in 2024, then surged by 89 bps to 0.01% in 2025, then dropped by 29 bps to 0.01% in 2026.
• Business Quant data shows XLO's Return on Sales at 0.01% in Q1 2026, 0.01% in Q4 2025, and 0.0% in Q3 2025.